T Lymphocyte News and Research

RSS

Promethera presents new preclinical NASH-Fibrosis data from HepaStem program at AASLD meeting

Promethera Biosciences SA, a world-leading cell therapy and regenerative medicine company targeting liver diseases, today announced the presentation of new preclinical NASH-Fibrosis data from its proprietary HepaStem program, demonstrating a beneficial effect of HepaStem in a nonalcoholic steatohepatitis (NASH) mouse model and confirming Hepastem’s unique and multifaceted mode of action.

15 Nov 2016

Immune checkpoint cancer therapies may cause rare cardiac side effects linked to unexpected immune response

Combination therapy utilizing two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response.

4 Nov 2016

New Penn Medicine study raises questions about NLR as biomarker for bladder cancer

A blood test that has shown promise in predicting how cancer will progress and what treatments will be most effective for a given patient may not be reliable for either, according to a new Penn Medicine study published this week in Cancer, a peer-reviewed journal of the American Cancer Society.

27 Oct 2016

Identification of new lung cancer subtypes could lead to personalized immunotherapies

Personalized therapies can potentially improve the outcomes of patients with lung cancer, but how to best design such an approach is not always clear.

24 Oct 2016

Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

Skin phenotype of pediatric eczema opens door for personalized treatment of AD in infants

Researchers for the first time have identified the skin phenotype of pediatric eczema or atopic dermatitis (AD) in infants, opening the door for personalized treatment approaches for young children with eczema.

23 Sep 2016

Researchers develop innovative technique for detecting HIV hiding places in infected patients

Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS cure.

19 Sep 2016

Researchers discover how mineral ion leaked from dying tumour tissue stops work of immune cells

Researchers at the National Cancer Institute in the USA and the Babraham Institute, UK, have discovered how a mineral ion leaked from tumour tissue as it dies acts to stop the work of anti-tumour immune cells.

18 Sep 2016

Researchers discover protein that plays role in onset of type 1 diabetes

A new study reveals a counterintuitive cellular strategy that may protect insulin-producing cells from destruction during type 1 diabetes.

31 Aug 2016

MedUni Vienna scientists aim to identify prognostic markers for cutaneous lymphomas

Primary cutaneous lymphomas, cancers of the lymphatic system, occur in the skin and originate either from T-lymphocytes (T-cell lymphomas, incidence 75%) or in B-cell lymphocytes (B-cell lymphomas, 25%).

30 Aug 2016

Research findings could lead to new ways of preventing or treating organ transplant rejection

An international team led by researchers from the University of Pittsburgh School of Medicine found that targeting certain donor cells lowered the risk of organ rejection in mice that underwent kidney and heart transplants.

24 Aug 2016

Seeds of tropical shrub guarana contain ten times more amount of catechins than green tea

The millions of people who consume green tea all over the world benefit from the catechins it contains.

22 Aug 2016

ECTRIMS previews important sessions ahead of world’s largest annual congress of multiple sclerosis

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) previews the key sessions ahead of its annual congress – a dedicated platform to promote and enhance research in Multiple Sclerosis. The 32nd edition of the world’s largest congress of multiple sclerosis will take place in London from 14 – 17 September 2016.

17 Aug 2016

Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget.

12 Jul 2016

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.

12 Jul 2016

Scientists discover link between two genes involved in PD and autoimmune diseases

A study publish in the journal CELL indicates that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease.

27 Jun 2016

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Salsalate has no greater effect than placebo on the progression of coronary artery plaque, show the findings of the randomised TINSAL-CVD trial.

3 Jun 2016

Diets rich in fruits and vegetables can help prevent chronic inflammation

A new study by the University of Liverpool's Institute of Ageing and Chronic Disease has identified food stuffs that can help prevent chronic inflammation that contributes to many leading causes of death.

17 May 2016

Real risk of rebound syndrome following fingolimod cessation for MS

Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs.

4 May 2016

KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.

21 Apr 2016